Nicox: Vyzulta approved in Hong Kong and Argentina
(CercleFinance.com) - Ophthalmology specialist Nicox announces that its licensed partner, Bausch-Lomb, has received marketing approval for Vyzulta (bunod latanoprostene ophthalmic solution), 0.
024% in Hong Kong and Argentina.
With these approvals, this product - indicated for the reduction of intraocular pressure in patients with open angle glaucoma or ocular hypertension - is now approved for commercialisation in five countries and territories.
For the record, the French biopharmaceutical company receives increasing net royalties of 6% to 12% on Vyzulta's global sales as well as future milestone payments of up to 150 million dollars.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
024% in Hong Kong and Argentina.
With these approvals, this product - indicated for the reduction of intraocular pressure in patients with open angle glaucoma or ocular hypertension - is now approved for commercialisation in five countries and territories.
For the record, the French biopharmaceutical company receives increasing net royalties of 6% to 12% on Vyzulta's global sales as well as future milestone payments of up to 150 million dollars.
Copyright (c) 2020 CercleFinance.com. All rights reserved.